 bolu versu infus regimen etoposid cisplatin treatment non-smal cell lung cancer studi north central cancer treatment group effort hypothesi durat cellular exposur cisplatin cddp import determin cytotox phase iii trial outpati bolu regimen combin cddp sequenti infus hour drug patient stage IV non-smal cell lung cancer surviv primari end point patient studi assess respons surviv toxic major respons patient bolu regimen patient infus therapi median time progress day bolu infus therapi median surviv time day studi result consist possibl infus therapi improv median surviv i.e month month toxic myelosuppress infus regimen infus therapi protocol cddp advantag respons rate time progress surviv bolu therapi addit infus therapi degre neutropenia treatment-rel death